Country: Canada
Language: English
Source: Health Canada
CEFOXITIN (CEFOXITIN SODIUM)
TEVA CANADA LIMITED
J01DC01
CEFOXITIN
1G
POWDER FOR SOLUTION
CEFOXITIN (CEFOXITIN SODIUM) 1G
INTRAMUSCULAR
10ML
Prescription
CEPHAMYCINS
Active ingredient group (AIG) number: 0113134002; AHFS:
APPROVED
1999-09-14
PRODUCT MONOGRAPH CEFOXITIN FOR INJECTION USP 1 g, 2 g and 10 g vials ANTIBIOTIC Teva Canada Limited Date of Revision: 30 Novopharm Court November 16, 2023 Toronto, Ontario Canada M1B 2K9 Control #:259940 PRODUCT MONOGRAPH CEFOXITIN FOR INJECTION 1 g, 2 g and 10 g vials THERAPEUTIC CLASSIFICATION Antibiotic ACTION AND CLINICAL PHARMACOLOGY Cefoxitin is a cephamycin derived from cephamycin C. Evidence from _in vitro_ studies suggests that Cefoxitin exerts its bactericidal action through the inhibition of bacterial cell wall synthesis. Studies have indicated that the resistance of Cefoxitin to degradation by bacterial beta- lactamases is due to the methoxy group in the 7α position. After intravenous or intramuscular administration of a 1 g dose, high serum concentrations are attained which rapidly decline to about 2 µg/mL at 3 hours in persons with normal renal function. The area under the plasma level-time curve is comparable after bolus injection or intravenous infusion over a period of 120 minutes. INDICATIONS AND CLINICAL USE TREATMENT For the treatment of the following infections when due to susceptible organisms: 1 - Intra-abdominal infections such as peritonitis and intra-abdominal abscess 2 - Gynecological infections such as endometritis and pelvic cellulitis 3 - Septicemia 4 - Urinary tract infections (including those caused by _Serratia marcescens_ and _Serratia spp_.) 5 - Lower respiratory tract infections 6 - Bone and joint infections caused by _Staphylococcus aureus_ 7 - Soft tissue infections such as cellulitis, abscesses and wound infections The susceptibility of the causative organism(s) to Cefoxitin for Injection should be determined by conducting appropriate culture and susceptibility studies. Therapy may be initiated while awaiting these test results. Adjustments in treatment may be required once these results become available. Organisms particularly appropriate for therapy with Cefoxitin for Injection are: GRAM POSITIVE Staphylococci: penicillinase producing and non-producing Streptococci excl Read the complete document